Reporting of adverse drug reactions by poison control centres in the US

Drug Safety

Volumn 23, Issue 1, 2000, Pages 87-93

  Chyka, Peter A ^a   McCommon, Steven W ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; DATA ANALYSIS; DRUG FATALITY; DRUG INFORMATION; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; NURSE; PHARMACIST; PHYSICIAN; POISON CENTER; POLICY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RESPONSIBILITY; REVIEW; TIME; UNITED STATES; WORKLOAD;

EID: 0033923893     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023010-00006     Document Type: Review

References (39)

1. 1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
2. 2. Aparasu RR. Visits to office-based physicians in the United States for medication-related morbidity. J Am Pharm Assoc 1999; 39: 332-7
3. 3. Johnson JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med 1995; 155: 1949-56
4. 4. Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet 1998; 351: 643-4
5. 5. Bates DW. Drugs and adverse drag reactions. How worried should we be? JAMA 1998; 279: 1216-7
6. 6. Kessler DA. Introducing MEDWatch: New approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765-8
7. 7. Cullen DJ, Bates DW, Small SD, et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. J Qual Improvement 1995: 21: 541-8
8. 8. Generali JA, Danish MA, Rosenbaum SE. Knowledge of and attitudes about adverse drug reaction reporting among Rhode Island pharmacists. Ann Pharmacother 1995; 29: 365-9
9. 9. Rogers AS, Israel E, Smith CR, et al. Physician knowledge, attitudes, and behavior related to reporting adverse drag events. Arch Intern Med 1988; 148: 1596-1600
10. 10. Annual adverse drug experience report: 1996. Washington DC: Surveillance and Data Processing Branch, Division of Pharmacovigilance and Epidemiology, Office of Epidemiology and Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration [online]. Available at: URL: http: //www.fda.gov/cder/dpe/annrep96/index.htm. [Accessed 1999 Oct 22]
11. 11. Youniss J, Litovitz TL, Villanueva P. Characterization of U.S. poison centers: a 1998 survey conducted by the American Association of Poison Control Centers. Vet Human Toxicol 2000; 42: 42-53
12. 12. Litovitz T. The TESS database. Use in product safety assessment. Drug Safe 1998; 18: 9-19
13. 13. Litovitz TL, Klein-Schwartz W, Caravati EM, et al. 1998 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1999; 17: 435-87
14. 14. Rosner B. Fundamentals of biostatistics. 4th ed. Belmont (CA): Wadsworth; 1995: 352-70
15. 15. Schiff G. Monitoring and reporting adverse drug reactions. Infusion 1985; 9 (6): 168-72
16. 16. Scott HD, Thacher-Renshaw A, Rosenbaum SE, et al. Physician reporting of adverse drug reactions. JAMA 1990; 263: 1785-8
17. 17. Veltri JC, McElwee NE, Schumacher MC. Interpretation and uses of data collected in poison control centres in the United States. Med Toxicol 1987; 2: 389-97
18. 18. Jick H, Garcia Rodriguez LA, Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998; 352: 1767-70
19. 19. Love JN, Litovitz TL, Howell JM, et al. Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers data from 1985 to 1995. J Toxicol Clin Toxicol 1997; 35: 353-9
20. 20. Litovitz T, Manoguerra A. Comparison of pediatric poisoning hazards: an analysis of 3.8 million exposure incidents. A report from the American Association of Poison Control Centers. Pediatrics 1992; 89: 999-1006
21. 21. Krenzelok EP, Litovitz T, Lippold KP, et al. Cimetidine toxicity: an assessment of 881 cases. Ann Emerg Med 1987; 16: 1217-21
22. 22. Martin AC, Caravati EM, Crouch BI, et al. Poison exposures in the elderly: a five-year descriptive study [abstract]. J Toxicol Clin Toxicol 1999; 37: 593
23. 23. Dyer JE, R Kreutzer R, Quattrone A, et al. Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR Morb Mortal Wkly Rep 1990: 39: 861-3
24. 24. Wax P, May J. Tracking iatrogenic poisoning fatalities using the American Association of Poison Control Centers Toxic Exposure Surveillance System [abstract]. Ann Emerg Med 1999; 34 (Pt 2): S29
25. 25. Litovitz T, Clancy C, Korberly B, et al. Surveillance of loperamide ingestions: an analysis of 216 poison center reports. J Toxicol Clin Toxicol 1997; 35: 11-9
26. 26. Litovitz T. Implication of dispensing cups in dosing errors and pediatric poisonings: a report from the American Association of Poison Control Centers. Ann Pharmacother 1992; 26: 917-8
27. 27. Hopkins U, Klein-Schwartz W, Anderson B, et al. Methylphenidate exposures: 5 years of poison center experience [abstract]. J Toxicol Clin Toxicol 1999; 37: 648
28. 28. Woolf A, Burkhart K, Caraccio T, et al. Self-poisoning among adults using multiple transdermal nicotine patches. J Toxicol Clin Toxicol 1996; 34: 691-8
29. 29. Woolf A, Burkhart K, Caraccio T, et al. Childhood poisoning involving transdermal nicotine patches. Pediatrics 1997; 99 (5): E4 [online]. Available from: URL: http:/www.pediatrics.org/ cgi/cont/abstract/99/5/e4 [Accessed 1999 Oct 22]
30. 30. Klein-Schwartz W. Toxicity of polysaccharide-iron complex exposures reported to poison control centers. Ann Pharmacother 2000; 34: 165-9
31. 31. Mowry J, Sanftleben J, Smith J. Eighteen month retrospective evaluation of Seroquel exposures [abstract]. J Toxicol Clin Toxicol 1999; 37: 631
32. 32. Smilkstein MJ, Burton BT, Keene W, et al. Acute respiratory illness linked to use of aerosol leather conditioner. Oregon, December 1992. MMWR Morb Mortal Wkly Rep 1993; 41: 965-7
33. 33. Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Safe 1998; 19: 1-10
34. 34. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-21
35. 35. Meyboom RHB, Hekster YA, Egberts ACG, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Safe 1997; 17: 374-89
36. 36. Task Force on Risk Management. Managing the risks from medical product use: creating a risk management framework. US Department of Health and Human Services, Food and Drug Administration [online]. Available at: URL: http: //www.fda.gov/oc/tfrm/riskmanagement.pdf. [Accessed 1999 May 25]
37. 37. Calvert WS, Holihan V. Pharmaceutical Research and Manufacturers of America/Food and Drug Administration cooperation in building capabilities for electronic submission of postmarketing safety data. Drug Infor J 1999; 33: 1093-99
38. 38. Chyka PA. Role of US poison centers in adverse drug reactions monitoring. Vet Human Toxicol 1999; 41: 400-2
39. 39. Institute of Medicine Committee on Quality of Health Care in America. Int: Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human: building a safer health system. Washington, DC: National Academy Press, 1999